These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 27286443)

  • 1. Physiological growth hormone replacement and rate of recurrence of craniopharyngioma: the Genentech National Cooperative Growth Study.
    Smith TR; Cote DJ; Jane JA; Laws ER
    J Neurosurg Pediatr; 2016 Oct; 18(4):408-412. PubMed ID: 27286443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth Hormone Therapy Does Not Increase the Risk of Craniopharyngioma and Nonfunctioning Pituitary Adenoma Recurrence.
    Losa M; Castellino L; Pagnano A; Rossini A; Mortini P; Lanzi R
    J Clin Endocrinol Metab; 2020 May; 105(5):. PubMed ID: 32112101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analyses of treatment variables for patients with childhood craniopharyngioma--results of the multicenter prospective trial KRANIOPHARYNGEOM 2000 after three years of follow-up.
    Müller HL; Gebhardt U; Schröder S; Pohl F; Kortmann RD; Faldum A; Zwiener I; Warmuth-Metz M; Pietsch T; Calaminus G; Kolb R; Wiegand C; Sörensen N;
    Horm Res Paediatr; 2010; 73(3):175-80. PubMed ID: 20197669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?
    Nguyen Quoc A; Beccaria K; González Briceño L; Pinto G; Samara-Boustani D; Stoupa A; Beltrand J; Besançon A; Thalassinos C; Puget S; Blauwblomme T; Alapetite C; Bolle S; Doz F; Grill J; Dufour C; Bourdeaut F; Abbou S; Guerrini-Rousseau L; Leruste A; Brabant S; Cavadias I; Viaud M; Boddaert N; Polak M; Kariyawasam D
    J Clin Endocrinol Metab; 2023 Jul; 108(8):1929-1936. PubMed ID: 36794424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up.
    Olsson DS; Buchfelder M; Wiendieck K; Kremenevskaja N; Bengtsson BÅ; Jakobsson KE; Jarfelt M; Johannsson G; Nilsson AG
    Eur J Endocrinol; 2012 Jun; 166(6):1061-8. PubMed ID: 22457235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GH replacement does not increase the risk of recurrence in patients with craniopharyngioma.
    Karavitaki N; Warner JT; Marland A; Shine B; Ryan F; Arnold J; Turner HE; Wass JA
    Clin Endocrinol (Oxf); 2006 May; 64(5):556-60. PubMed ID: 16649976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Physiologic Growth Hormone-Replacement Therapy and Craniopharyngioma Recurrence in Pediatric Patients: A Meta-Analysis.
    Alotaibi NM; Noormohamed N; Cote DJ; Alharthi S; Doucette J; Zaidi HA; Mekary RA; Smith TR
    World Neurosurg; 2018 Jan; 109():487-496.e1. PubMed ID: 28987837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of primary cancers and intracranial tumour recurrences in GH-treated and untreated adult hypopituitary patients: analyses from the Hypopituitary Control and Complications Study.
    Child CJ; Conroy D; Zimmermann AG; Woodmansee WW; Erfurth EM; Robison LL
    Eur J Endocrinol; 2015 Jun; 172(6):779-90. PubMed ID: 25810462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with craniopharyngiomas: therapeutical difficulties with growth hormone.
    Cannavò S; Marini F; Trimarchi F
    J Endocrinol Invest; 2008 Sep; 31(9 Suppl):56-60. PubMed ID: 19020388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of growth hormone treatment in children with craniopharyngioma with reference to the KIGS (Kabi International Growth Study) database.
    Price DA; Jönsson P
    Acta Paediatr Suppl; 1996 Oct; 417():83-5. PubMed ID: 9055921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.
    Verweij T; Slagboom TNA; van Varsseveld NC; van der Lely AJ; Drent ML; van Bunderen CC
    Eur J Endocrinol; 2021 Oct; 185(6):793-801. PubMed ID: 34605771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome in children with recurrent craniopharyngioma after primary surgery.
    Kalapurakal JA; Goldman S; Hsieh YC; Tomita T; Marymont MH
    Cancer J; 2000; 6(6):388-93. PubMed ID: 11131489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrence of sellar and suprasellar tumors in children treated with hGH--relation to immunohistochemical study on GH receptor.
    Uchino Y; Saeki N; Iwadate Y; Yasuda T; Konda S; Watanabe T; Wada K; Kazukawa I; Higuchi Y; Iuchi T; Tatsuno I; Yamaura A
    Endocr J; 2000 Mar; 47 Suppl():S33-6. PubMed ID: 10890179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term safety of recombinant human growth hormone in turner syndrome.
    Bolar K; Hoffman AR; Maneatis T; Lippe B
    J Clin Endocrinol Metab; 2008 Feb; 93(2):344-51. PubMed ID: 18000090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database).
    Darendeliler F; Karagiannis G; Wilton P; Ranke MB; Albertsson-Wikland K; Anthony Price D; On Behalf Of The Kigs International Board
    Acta Paediatr; 2006 Oct; 95(10):1284-90. PubMed ID: 16982503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative pituitary hormonal disturbances and hormone replacement therapy time and dosage in children with craniopharyngiomas.
    Li GM; Sun XJ; Shao P
    Chin Med J (Engl); 2008 Oct; 121(20):2077-82. PubMed ID: 19080279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Risks of Contributing Factors to Morbidity and Mortality in Adults With Craniopharyngioma on Growth Hormone Replacement.
    Yuen KCJ; Mattsson AF; Burman P; Erfurth EM; Camacho-Hubner C; Fox JL; Verhelst J; Geffner ME; Abs R
    J Clin Endocrinol Metab; 2018 Feb; 103(2):768-777. PubMed ID: 29029108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effect of recombinant human growth hormone therapy on metabolic parameters in patients with craniopharyngioma].
    Mao JF; Wang X; Xiong SY; Zheng JJ; Yu BQ; Nie M; Wu XY; Qi ST
    Zhonghua Yi Xue Za Zhi; 2017 Nov; 97(42):3286-3290. PubMed ID: 29141371
    [No Abstract]   [Full Text] [Related]  

  • 19. Craniopharyngiomas in children: recurrence, reoperation and outcome.
    Vinchon M; Dhellemmes P
    Childs Nerv Syst; 2008 Feb; 24(2):211-7. PubMed ID: 17786455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypothalamic involvement predicts cardiovascular risk in adults with childhood onset craniopharyngioma on long-term GH therapy.
    Holmer H; Ekman B; Björk J; Nordstöm CH; Popovic V; Siversson A; Erfurth EM
    Eur J Endocrinol; 2009 Nov; 161(5):671-9. PubMed ID: 19667040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.